Quinupristin-Dalfopristin Combined with β-Lactams for Treatment of Experimental Endocarditis Due to Staphylococcus aureus Constitutively Resistant to Macrolide-Lincosamide-Streptogramin B Antibiotics

Abstract

Quinupristin-dalfopristin (Q-D

2015 ESC Guidelines for the management of infective endocarditis

“…Inne alternatywne schematy leczenia obejmują fosfomicynę z imipenemem [175], nowsze b-laktamy z dość wysokim powinowactwem do PBP2a, takie jak ceftarolina [176], chinupristynę-dalfopristynę w połączeniu z b-laktamami lub w monoterapii [177,178], b-laktamy w skojarzeniu z oksazolidinodionami (linezolid) [179], b-laktamy z wankomycyną [180] oraz trimetoprym/sulfametoksazol w dużych dawkach łącznie z klindamycyną [160]. W takich przypadkach leczenie należy prowadzić we współpracy ze specjalistą chorób zakaźnych.…”

In Vivo Synergism of Ceftobiprole and Vancomycin against Experimental Endocarditis Due to Vancomycin-Intermediate Staphylococcus aureus

“…The production of catheter-induced aortic vegetations and the installation of the infusion pump device to deliver the antibiotics were performed in female Wistar rats (Charles River Laboratories, L'Arbresle, France) as described previously (18,25). The administration of drug combinations necessitated the use of two infusion pumps (one for each drug) (46). Valve infections were induced 24 h after catheterization by intravenous (i.v.)…”

In Vitro Activities of Quinupristin-Dalfopristin and Cefepime, Alone and in Combination with Various Antimicrobials, against Multidrug-Resistant Staphylococci and Enterococci in an In Vitro Pharmacodynamic Model

“…We failed to detect MIC elevations even in those models where significant bacterial regrowth occurred. Interactions of Q-D and other antimicrobials have also been studied in animal models of infection (20,33,34).…”